Drugs / Lacrifill
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07510620 | Dec 2025 → Jul 2026 overdue | dry eye syndrome | Vision Innovation Centers of Pennsylvania, LLC d/b/a Eye Care Specialists | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-09 | Nordic Pharma SAS | Regulatory Nordic Pharma Announces CE Mark Approval for Lacrifill® Canalicular Gel, Paving the Way for European Launch nordicpharma.com ↗
Nordic Group B.V., an international pharmaceutical company operating as Nordic Pharma, announced today that Lacrifill®, a novel therapy for dry eye, has just received CE mark approval. |
| 2024-05-29 | Nordic Pharma SAS | Regulatory NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES THE LAUNCH OF LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE. nordicpharma.com ↗
LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacrifill | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07510620 ↗ |
| Modality | Other / unclassified | “Lacrifill is a cross-linked hyaluronic acid derivative” NCT07510620 ↗ |